Trial Profile
An Adaptive Phase 3, Randomized, Double-blind, Placebo-controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 07 Sep 2020 Status changed from active, no longer recruiting to completed.
- 01 Sep 2020 According to a Sanofi media release, detailed results from the study will be submitted to a peer-reviewed publication later in 2020.
- 01 Sep 2020 Results published in the Sanofi Media Release.